Polyclonal Antibody to Vascular Endothelial Growth Factor Receptor 3 (VEGFR3)
| Code | Size | Price |
|---|
| PAB893Mu01-20ul | 20ul | £86.00 |
Quantity:
| PAB893Mu01-100ul | 100ul | £158.00 |
Quantity:
| PAB893Mu01-200ul | 200ul | £214.00 |
Quantity:
| PAB893Mu01-1ml | 1ml | £488.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
FLT41; FLT4; PCL; Fms-Related Tyrosine Kinase 4; Tyrosine-protein kinase receptor FLT4
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Vascular Endothelial Growth Factor Receptor 3
Reactivity:
Hu;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:500-2000<br/>Immunohistochemistry: 5-20ug/mL;1:50-200<br/>Immunocytochemistry: 5-20ug/mL;1:50-200<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) | RPB893Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||